1. Wagner VP, Webber LP, Salvadori G, Meurer L, Fonseca FP, Castilho RM, et al. Overexpression of MutSα complex proteins predicts poor prognosis in oral squamous cell carcinoma. Med (United States). 2016;95:1-8.

https://doi.org/10.1097/MD.0000000000003725

PMid:27258499 PMCid:PMC4900707

2. González-Ramírez I, García-Cuellar C, Sánchez-Pérez Y, Granados-García M. DNA methylation in oral squamous cell carcinoma: Molecular mechanisms and clinical implications. Oral Dis. 2011;17:771-8.

https://doi.org/10.1111/j.1601-0825.2011.01833.x

PMid:21781230 

3. Vasan K, Satgunaseelan L, Anand S, Asher R, Selinger C, Low TH, et al. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma. Pathology. 2019;51:688-95.

https://doi.org/10.1016/j.pathol.2019.08.005

PMid:31630878 

4. Brägelmann J, Dagogo-Jack I, El Dinali M, Stricker T, Brown CD, Zuo Z, et al. Oral cavity tumors in younger patients show a poor prognosis and do not contain viral RNA. Oral Oncol. 2013;49:525-33.

https://doi.org/10.1016/j.oraloncology.2013.02.003

PMid:23490885 

5. Caldeira PC, Aguiar MCF, Mesquita RA, do Carmo MAV. Oral leukoplakias with different degrees of dysplasia: Comparative study of hMLH1, p53, and AgNOR. J Oral Pathol Med. 2011;40:305-11.

https://doi.org/10.1111/j.1600-0714.2010.01000.x

PMid:21208285 

6. Caldeira PC, Abreu MHNG, Batista AC, Do Carmo MAV. hMLH1 immunoexpression is related to the degree of epithelial dysplasia in oral leukoplakia. J Oral Pathol Med. 2011;40:153-9.

https://doi.org/10.1111/j.1600-0714.2010.00963.x

PMid:20969633 

7. Jessri M, Dalley AJ, Farah CS. HMSH6: A potential diagnostic marker for oral carcinoma in situ. J Clin Pathol. 2015;68:86-90.

https://doi.org/10.1136/jclinpath-2014-202411

PMid:25352643 

8. Jessri M, Dalley AJ, Farah CS. MutSα and MutLα immunoexpression analysis in diagnostic grading of oral epithelial dysplasia and squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119:74-82.

https://doi.org/10.1016/j.oooo.2014.06.017

PMid:25446502 

9. Chaudhari N, Tupkari J, Joy T, Ahire M. Human MutL homolog 1 immunoexpression in oral leukoplakia and oral squamous cell carcinoma: A prospective study in Indian population. J Oral Maxillofac Pathol. 2016;20:453-61.

https://doi.org/10.4103/0973-029X.190948

PMid:27721611 PMCid:PMC5051294

10. Fukuhara S, Chang I, Mitsui Y, Chiyomaru T, Yamamura S, Majid S, et al. Functional role of DNA mismatch repair gene PMS2 in prostate cancer cells. Oncotarget. 2015;6:16341-51.

https://doi.org/10.18632/oncotarget.3854

PMid:26036629 PMCid:PMC4599273

11. Goodenberger ML, Thomas BC, Riegert-Johnson D, Boland CR, Plon SE, Clendenning M, et al. PMS2 monoallelic mutation carriers: The known unknown. Genet Med. 2016;18:13-9.

https://doi.org/10.1038/gim.2015.27

PMid:25856668 PMCid:PMC4834863

12. Li M, Zhang Q, Liu L, Lu W, Wei H, Li RW, et al. Expression of the Mismatch Repair Gene hMLH1 Is Enhanced in Non-Small Cell Lung Cancer with EGFR Mutations. PLoS One. 2013;8:1-7.

https://doi.org/10.1371/journal.pone.0078500

PMid:24205245 PMCid:PMC3812034

13. Polom K, Marrelli D, Pascale V, Ferrara F, Voglino C, Marini M. The pattern of lymph node metastases in microsatellite unstable gastric cancer. Eur J Surg Oncol. 2017;43:2341-8.

https://doi.org/10.1016/j.ejso.2017.09.007

PMid:28942235 

14. Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, et al. Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. Carcinogenesis. 2017;38:19-27.

https://doi.org/10.1093/carcin/bgw116

PMid:27803051 

15. Gibson SL, Narayanan L, Hegan DC, Buermeyer AB, Liskay RM, Glazer PM. Overexpression of the DNA mismatch repair factor, PMS2, confers hypermutability and DNA damage tolerance. Cancer Lett. 2006;244:195-202.

https://doi.org/10.1016/j.canlet.2005.12.009

PMid:16426742 

16. Lydiatt W, O'Sullivan B, Patel S. Major Changes in Head and Neck Staging for 2018. Am Soc Clin Oncol Educ B. 2018;38:505-14.

https://doi.org/10.1200/EDBK_199697

PMid:30231400 

17. Dantas TS, de Barros Silva PG, Verde MEQL, Ribeiro Júnior A de L, Cunha M do PSS, Mota MRL, et al. Role of inflammatory markers in prognosis of oral squamous cell carcinoma. Asian Pacific J Cancer Prev. 2019;20:3635-42.

https://doi.org/10.31557/APJCP.2019.20.12.3635

PMid:31870104 PMCid:PMC7173367

18. Pereira CS, de Oliveira MVM, Barros LO, Bandeira GA, Santos SHS, Basile JR, et al. Low expression of MSH2 DNA repair protein is associated with poor prognosis in head and neck squamous cell carcinoma. J Appl Oral Sci. 2013;21:416-21.

https://doi.org/10.1590/1679-775720130206

PMid:24212987 PMCid:PMC3881843

19. Aronson M, Holter S, Semotiuk K, Winter L, Pollett A, Gallinger S, et al. DNA mismatch repair status predicts need for future colorectal surgery for metachronous neoplasms in young individuals undergoing colorectal cancer resection. Dis Colon Rectum. 2015;58:645-52.

https://doi.org/10.1097/DCR.0000000000000391

PMid:26200678 

20. Li M, Liu L, Wang Z, Wang L, Liu Z, Xu G, et al. Overexpression of hMSH2 and hMLH1 protein in certain gastric cancers and their surrounding mucosae. Oncol Rep. 2008;19:401-6.

https://doi.org/10.3892/or.19.2.401

PMid:18202787 

21. Fonseca ALA, Prosdocimi F, Bianco B, Perez MM, Fonseca FLA, da Costa Aguiar Alves B. Involvement of repair genes in oral cancer: A systematic review. Cell Biochem Funct. 2019;37:572-7.

https://doi.org/10.1002/cbf.3428

PMid:31502267 

22. Czerninski R, Krichevsky S, Ashhab Y, Gazit D, Patel V, Ben-Yehuda D. Promoter hypermethylation of mismatch repair genes, hMLH1 and hMSH2 in oral squamous cell carcinoma. Oral Dis. 2009;15:206-13.

https://doi.org/10.1111/j.1601-0825.2008.01510.x

PMid:19207881 

23. Iype EM, Pandey M, Mathew A, Thomas G, Sebastian P, Nair MK. Oral cancer among patients under the age of 35 years. J Postgrad Med. 2001;47:171-6.

PMid:11832617

24. Dantas TS, De Barros Silva PG, Sousa EF, Da Cunha MDP, De Aguiar ASW, Costa FWG, et al. Influence of educational level, stage, and histological type on survival of oral cancer in a brazilian population: A retrospective study of 10 years observation. Med (United States). 2016;95:1-10.

https://doi.org/10.1097/MD.0000000000002314

PMid:26817864 PMCid:PMC4998238

25. Nicolaides NC, Littman SJ, Modrich P, Kinzler KW, Vogelstein B. A Naturally Occurring hPMS2 Mutation Can Confer a Dominant Negative Mutator Phenotype. Mol Cell Biol. 1998;18:1635-41.

https://doi.org/10.1128/MCB.18.3.1635

PMid:9488480 PMCid:PMC108878

26. Kato MG, Baek C-H, Chaturvedi P, Gallagher R, Kowalski LP, Leemans CR, et al. Update on oral and oropharyngeal cancer staging - International perspectives. World J Otorhinolaryngol - Head Neck Surg. 2020;6:66-75.

https://doi.org/10.1016/j.wjorl.2019.06.001

PMid:32426706 PMCid:PMC7221211

27. Adachi M, Ijichi k, Hasegawa Y, Nakamura H, Ogawa T, Kanematsu N. Human MLH1 status can potentially predict cisplatin sensitivity but not microsatellite instability in head and neck squamous cell carcinoma cells. Exp Ther Med. 2010;1:93-86.

https://doi.org/10.3892/etm_00000017

PMid:23136600 PMCid:PMC3490332